“…In the recent past, CAs belonging to the β -CA family have emerged as potential targets for developing drugs against diseases caused by bacterial and parasitic pathogens. Indeed, several in vitro inhibition studies have shown that the β -CAs from pathogenic bacteria and parasitic pathogens can be inhibited by certain compounds [12,13,14,15,16,17,18,19,20,21,22,23,24]. Among these inhibitors are sulfonamides and their bioisosteres, which are the main classes of CA inhibitors that have been in clinical use for more than 50 years [25,26,27,28].…”